|
Oct 10
|
TransCode Therapeutics Completes Initial Dosing of First Cohort in Phase 1 Clinical Trial with TTX-MC138, a microRNA-Targeted Technology
|
|
Sep 5
|
TransCode Therapeutics Awarded $2 Million NIH Grant to Support Clinical Evaluation of Lead Candidate
|
|
Jul 24
|
TransCode Therapeutics, Inc. Announces Closing of Public Offering
|
|
Feb 20
|
TransCode Therapeutics Reports Publication of United States Patent Application Covering TransCode’s RIG-I Agonist Immunotherapeutic
|
|
Jan 12
|
TransCode Therapeutics Reports Further Restructuring to Reduce Expenses and Increased Focus on Planned Phase 1 Clinical Trial, Retirement of CEO
|
|
Jan 11
|
TransCode Therapeutics Announces 1-for-40 Reverse Stock Split
|
|
Dec 5
|
TransCode Therapeutics To Present Phase 0 Data at 2023 San Antonio Breast Cancer Symposium
|
|
Dec 4
|
TransCode Therapeutics Announces Closing of $1.2 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules
|
|
Nov 30
|
TransCode Therapeutics Announces $1.2 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules
|
|
Aug 23
|
TransCode Therapeutics Announces First Subject Dosed with Radiolabeled TTX-MC138 in First-In-Human Clinical Trial
|